Press Releases

Title: *

Category: *

User/Subject: *

Author Name: *

Unit: *

CTL/Team Lead Name: *

AME Name: *

Description: *

<p><a href="https://www.longdom.org/clinical-trials.html">Post-COVID-19 ILD is not a rare pathophysiology</a>. Corticosteroid therapy may improve prolonged respiratory symptoms, hypoxemia, and radiographical abnormalities. Coronavirus disease 2019 (COVID-19) is a global problem. Globally, there have been more than 300 million confirmed COVID-19 cases and more than 5 million deaths. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 <a href="https://www.longdom.org/clinical-trials/archive.html">(SARS-CoV-2). SARS-CoV-2</a> is known to cause severe acute pneumonia, while the clinical courses vary. Post COVID-19 Interstitial Lung Disease (ILD) is considered to be “Long COVID”, which is of great interest because it causes <a href="https://www.longdom.org/clinical-trials/instructionsforauthors.html">patients’ disabilities</a>, and the mechanisms, clinical course, and treatments have not been well elucidated. Generally, post-COVID-19 ILD is characterized by prolonged radiographical abnormalities such as pulmonary fibrosis (consolidation, irregular reticulation, traction bronchiectasis, etc.). Post infectious organized pneumonia is dominant in post- COVID-19 ILD, although other ILD patterns, such as nonspecific interstitial pneumonia and idiopathic <a href="https://www.longdom.org/submissions/clinical-trials.html">pulmonary fibrosis</a>, have also been reported</p>

Image: *

Add / Edit Press Release